CELL INTELLIGENCE · 肿瘤细胞治疗研究

开发基于溶瘤病毒递送 CD19 和 EGFRvIII 抗原与双特异性 CAR 的胶质母细胞瘤多模式治疗

Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.

CAR-T 治疗的疗效、安全性和成本效果

Efficacy, safety and cost-effectiveness of CAR-T therapy.

靶向癌症干细胞的 CAR 免疫疗法：生物学、证据和未来方向

Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions.

利用旁分泌 SIRPγ 衍生的 CD47 阻断剂增强抗 EGFRvIII CAR-T 细胞治疗对胶质母细胞瘤的疗效

Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker.

表达 CD19 CAR 的 iPSC 衍生 NK 细胞通过靶向肿瘤微环境中的周细胞有效增强向胶质母细胞瘤的迁移与细胞毒性

CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor micr

血脑屏障模型在靶向胶质母细胞瘤的 CAR-T 免疫治疗临床前评估中的应用

Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies.

2009 至 2021 年 CAR-T 细胞的文献计量学与知识图谱分析

A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.

作为一种具有巨大潜力和临床应用前景的抗肿瘤疗法，CAR-T 细胞疗法仍处于快速发展阶段。CAR-T 细胞相关领域在未来仍将是研究热点。